Finny logo
Finny logo
Dibs:
Dibs:
0

Verastem (VSTM) stock price is holding steady: what’s next?

5:38 am ET, 07 Aug 2018

Verastem, Inc. (VSTM) shares are trading at 7.60, down -2%.  What's driving VSTM stock price?  What's VSTM stock price forecast?

The shares of small oncology company rallied over 50% since mid-May, because the company's first product is likely to be approved by the FDA in October.  The stock has garnered analyst interest as of lately.  

Verastem took advantages of the rise in share price to announce a secondary offering priced at $4.50 a share. 

Let's look at the sentiment towards the VSTM stock.  Our technical analysis shows that: 

  • The stock short-term sentiment (next 30 days) is trending negative;
  • The mid-term sentiment (3-6 months) is trending positive;
  • The long-term sentiment (9-12 months) is positive. 

Over the last month, Verastem, Inc. (VSTM) returned +5.11%.

Verastem, Inc. (VSTM) average analyst price target ($13.33) is 70.68% above its current price ($7.81).

For the latest price and information on Verastem, Inc., please visit Finstead and search for "VSTM price" or "VSTM news".

Verastem (NASDAQ:VSTM): will the stock rebound post Q1 earnings?

5:23 pm ET, 15 May 2018

Verastem (NASDAQ:VSTM) released Q1 earnings today.  The EPS was -$0.41, which was $0.02 below analysts' expectations.  

What is the stock price forecast now?  What to analysts predict?

Per Finstead Research, the average analyst price target for Verastem is $11.80.  This presents a significant upside to the current price of $4.70 (visit Finstead and type "VSTM upside" or "VSTM price target").  

Now, let's look at the stock sentiment.  Based on the technical analysis, the short-, mid- and long-term forecast is relatively rosy.  

The company claims Q1'18 was a strong quarter, highlighted by the acceptance of the duvelisib New Drug Application (NDA) by the FDA. This drug treats patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and follicular lymphoma. 

The upcoming FDA review decision for duvelisib is due by the end of the year, and the company is building U.S. commercial capabilities for the drug's potential product launch in 2018. 

Verastem is also building out a world-class commercial team, led by Joseph Lobacki, who has demonstrated success in commercializing oncology drugs.

For the most recent news on Verastem, you can check Finstead VSTM news page, or visit Finstead and type "VSTM news".   

Verastem, Inc. (VSTM) Stock Guide

Updated at: 7:36 pm ET, 18 Sep 2020

Before we start: if you're looking for VSTM stock price, you can quickly find it out by visiting Finny and typing "VSTM quote". If you're looking for a quick scoop on VSTM stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "VSTM". You'll get all this info in one place. Or you can just type "VSTM news" to get the latest stock news.

Looking to buy or sell Verastem, Inc. (VSTM)? Interested in getting the full scoop on VSTM, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this VSTM stock guide, we'll address key questions about VSTM, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are VSTM earnings?
2. What is VSTM stock forecast (i.e., prediction)?
3. VSTM buy or sell? What is VSTM Finny Score?
4. What are the reasons to buy VSTM? Why should I buy VSTM stock?
5. What are the reasons to sell VSTM? Why should I sell VSTM stock?
6. What are VSTM key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are VSTM earnings?

VSTM trailing 12-month earnings per share (EPS) is -$1.23.

Analyst Predictions

2. What is VSTM stock forecast (i.e., prediction)?

Based on VSTM analyst price targets, VSTM stock forecast is $3.83 (for a year from now). That means the average analyst price target for VSTM stock is $3.83. The prediction is based on 5 analyst estimates.

The low price target for VSTM is $3.00, while the high price target is $5.00.

VSTM analyst rating is Buy.

Analysis

3. VSTM buy or sell? What is VSTM Finny Score?

#{finnyScore:88}Our quantitative analysis shows 7 reasons to buy and 1 reason to sell VSTM, resulting in Finny Score of 88.

4. What are the reasons to buy VSTM? Why should I buy VSTM stock?

Here are the reasons to buy VSTM stock:

5. What are the reasons to sell VSTM? Why should I sell VSTM stock?

Let's look at the reasons to sell VSTM stock (i.e., the bear case):

  • VSTM short share of float is 6.63%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See VSTM short share of float chart.

Key Stats

6. What are VSTM key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for VSTM:

Metrics VSTM
Price $1.17
Average Price Target / Upside $3.83 / 228.76%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 169
Market Cap $223.78M
Forward P/E Ratio -4.71
Price/Book Ratio 10.17
Revenue (TTM) $22.01M
YoY Quarterly Revenue Growth 37.30%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us